Ginkgo Bioworks

Summary

In 2009 was created Ginkgo Bioworks, which is appeared as Corporate Investor. The fund was located in North America if to be more exact in United States. The leading representative office of defined Corporate Investor is situated in the Boston.

Among the most successful fund investment fields, there are Chemical Engineering, Health Care. Among the various public portfolio startups of the fund, we may underline Synlogic For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

The real fund results show that this Corporate Investor is 5 percentage points more often commits exit comparing to other companies. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Ginkgo Bioworks performs on 4 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 50 - 100 millions dollars. The higher amount of exits for fund were in 2015.

This organization was formed by Austin Che, Barry Canton, Jason Kelly, Reshma Shetty, Tom Knight.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Ginkgo Bioworks, startups are often financed by OrbiMed, Mohr Davidow Ventures, DFJ. The meaningful sponsors for the fund in investment in the same round are Viking Global Investors, Bayer, Casdin Capital. In the next rounds fund is usually obtained by Viking Global Investors, Bayer.